RT Journal Article
SR Electronic
T1 A single-cell atlas of the peripheral immune response to severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20069930
DO 10.1101/2020.04.17.20069930
A1 Aaron J. Wilk
A1 Arjun Rustagi
A1 Nancy Q. Zhao
A1 Jonasel Roque
A1 Giovanny J. Martinez-Colon
A1 Julia L. McKechnie
A1 Geoffrey T. Ivison
A1 Thanmayi Ranganath
A1 Rosemary Vergara
A1 Taylor Hollis
A1 Laura J. Simpson
A1 Philip Grant
A1 Aruna Subramanian
A1 Angela J. Rogers
A1 Catherine A. Blish
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.17.20069930.abstract
AB There is an urgent need to better understand the pathophysiology of Coronavirus disease 2019 (COVID-19), the global pandemic caused by SARS-CoV-2. Here, we apply single-cell RNA sequencing (scRNA-seq) to peripheral blood mononuclear cells (PBMCs) of 7 patients hospitalized with confirmed COVID-19 and 6 healthy controls. We identify substantial reconfiguration of peripheral immune cell phenotype in COVID-19, including a heterogeneous interferon-stimulated gene (ISG) signature, HLA class II downregulation, and a novel B cell-derived granulocyte population appearing in patients with acute respiratory failure requiring mechanical ventilation. Importantly, peripheral monocytes and lymphocytes do not express substantial amounts of pro-inflammatory cytokines, suggesting that circulating leukocytes do not significantly contribute to the potential COVID-19 cytokine storm. Collectively, we provide the most thorough cell atlas to date of the peripheral immune response to severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Stanford ICU Biobank and A.J.R. are funded by NIH/NHLBI K23 HL125663. A.J.W. is supported by the Stanford Medical Scientist Training Program (T32 GM007365-44) and the Stanford Bio-X Interdisciplinary Graduate Fellowship; A.R. is supported by the Applied Genomics in Infectious Diseases training grant T32 AI007502-23; N.Q.Z. is supported by a National Science Scholarship from A*STAR Singapore; J.L.M. is supported by National Science Foundation Graduate Research Fellowship DGE-1656518; J.L.M. and G.I. are supported by NIH training grant T32 AI007290-35. C.A.B. is supported by NIH/NIDA DP1 DA04608902, a 2019 Sentinel Pilot Project from the Bill & Melinda Gates Foundation, and Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Diseases #1016687. C.A.B. is the Tashia and John Morgridge Faculty Scholar in Pediatric Translational Medicine from the Stanford Maternal Child Health Research Institute and an Investigator of the Chan Zuckerberg Biohub.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw sequencing data will be deposited on GEO. Processed count matrices will be hosted on and available for download from the publicly accessible cellxgene platform by the Chan Zuckerberg Biohub Initiative.